within Pharmacolibrary.Drugs.ATC.L;

model L01FX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0353 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC) comprised of a humanized monoclonal antibody linked to the cytotoxic agent calicheamicin. It is indicated for the treatment of adults with newly diagnosed or relapsed/refractory CD33-positive acute myeloid leukemia (AML). The drug is currently approved in several countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with relapsed or refractory AML. The model described is for the total antibody after intravenous administration (IV infusion).</p><h4>References</h4><ol><li><p>Masters, JC, et al., &amp; Knight, B (2019). Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical pharmacokinetics</i> 58(2) 271–282. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0694-x&quot;>10.1007/s40262-018-0694-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30022367/&quot;>https://pubmed.ncbi.nlm.nih.gov/30022367</a></p></li><li><p>Dowell, JA, et al., &amp; Berger, MS (2001). Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. <i>Journal of clinical pharmacology</i> 41(11) 1206–1214. DOI:<a href=&quot;https://doi.org/10.1177/00912700122012751&quot;>10.1177/00912700122012751</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11697753/&quot;>https://pubmed.ncbi.nlm.nih.gov/11697753</a></p></li><li><p>Buckwalter, M, et al., &amp; Mayer, PR (2004). Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. <i>Journal of clinical pharmacology</i> 44(8) 873–880. DOI:<a href=&quot;https://doi.org/10.1177/0091270004267595&quot;>10.1177/0091270004267595</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15286091/&quot;>https://pubmed.ncbi.nlm.nih.gov/15286091</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FX02;
